PL3278801T3 - Kompozycja farmaceutyczna zawierająca mirabegron - Google Patents

Kompozycja farmaceutyczna zawierająca mirabegron

Info

Publication number
PL3278801T3
PL3278801T3 PL16773147T PL16773147T PL3278801T3 PL 3278801 T3 PL3278801 T3 PL 3278801T3 PL 16773147 T PL16773147 T PL 16773147T PL 16773147 T PL16773147 T PL 16773147T PL 3278801 T3 PL3278801 T3 PL 3278801T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
composition containing
containing mirabegron
mirabegron
pharmaceutical
Prior art date
Application number
PL16773147T
Other languages
English (en)
Inventor
Seiji Takae
Toshiro Sakai
Yuki Kasashima
Yurina ANSEI
Tsuyoshi Kiyota
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL3278801T3 publication Critical patent/PL3278801T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
PL16773147T 2015-03-31 2016-03-31 Kompozycja farmaceutyczna zawierająca mirabegron PL3278801T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015073911A JP2018090490A (ja) 2015-03-31 2015-03-31 ミラベグロン含有医薬組成物
EP16773147.0A EP3278801B1 (en) 2015-03-31 2016-03-31 Pharmaceutical composition containing mirabegron
PCT/JP2016/060745 WO2016159267A1 (ja) 2015-03-31 2016-03-31 ミラベグロン含有医薬組成物

Publications (1)

Publication Number Publication Date
PL3278801T3 true PL3278801T3 (pl) 2020-03-31

Family

ID=57005157

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16773147T PL3278801T3 (pl) 2015-03-31 2016-03-31 Kompozycja farmaceutyczna zawierająca mirabegron

Country Status (14)

Country Link
US (1) US10058536B2 (pl)
EP (1) EP3278801B1 (pl)
JP (1) JP2018090490A (pl)
CY (1) CY1122352T1 (pl)
DK (1) DK3278801T3 (pl)
ES (1) ES2760673T3 (pl)
HR (1) HRP20192213T1 (pl)
HU (1) HUE046729T2 (pl)
LT (1) LT3278801T (pl)
PL (1) PL3278801T3 (pl)
PT (1) PT3278801T (pl)
RS (1) RS59626B1 (pl)
SI (1) SI3278801T1 (pl)
WO (1) WO2016159267A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6713734B2 (ja) * 2015-07-02 2020-06-24 三栄源エフ・エフ・アイ株式会社 粉体組成物のダマの形成を抑制する方法
CN111989102A (zh) * 2018-02-28 2020-11-24 大日本住友制药株式会社 水性混悬液型药物制剂
JPWO2019167978A1 (ja) * 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
KR102067261B1 (ko) * 2018-03-13 2020-01-16 충북대학교 산학협력단 미라베그론을 유효 성분으로 포함하는 서방형의 약학 조성물 및 이의 제조방법
US11583521B2 (en) * 2020-07-01 2023-02-21 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
CA3191262A1 (en) * 2020-09-01 2022-03-10 Rajneesh Taneja Methods of preparing modified dosage forms and related components
CN116472101A (zh) * 2020-09-01 2023-07-21 结核病药物开发全球联盟公司 制备改良型剂型和相关组分的方法
US11311518B1 (en) * 2021-06-29 2022-04-26 Jubilant Pharma Holdings Inc. Parenteral dosage form of β3 adrenoreceptor agonists
CN114617881A (zh) * 2022-02-19 2022-06-14 苏州海景医药科技有限公司 一种米拉贝隆组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2985714B2 (ja) 1995-03-20 1999-12-06 栗田工業株式会社 抗菌性組成物
KR100506568B1 (ko) 1997-10-17 2006-04-21 아스텔라스세이야쿠 가부시키가이샤 아미드유도체및이의염,및이를포함하는약제학적제제
US6514492B1 (en) * 1999-07-14 2003-02-04 Schering-Plough Veterinary Corporation Taste masking of oral quinolone liquid preparations using ion exchange resins
EP1204406A2 (en) 1999-07-29 2002-05-15 Roxane Laboratories, Inc. Opioid sustained-released formulation
JP3795365B2 (ja) 2001-09-28 2006-07-12 和光堂株式会社 服薬補助食品
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2503570C (en) 2002-11-07 2011-04-19 Yamanouchi Pharmaceutical Co., Ltd. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
JP4211668B2 (ja) 2004-04-21 2009-01-21 キユーピー株式会社 ゾル状又はゲル状食品調製用粉末組成物
CN1879610A (zh) 2006-04-03 2006-12-20 哈尔滨工业大学 口服多肽药物缓释微胶囊的制备方法
JP3930897B1 (ja) 2006-08-16 2007-06-13 太陽化学株式会社 粘度発現性を改良した増粘用組成物
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2832730A4 (en) 2012-03-30 2015-09-09 Astellas Pharma Inc MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION

Also Published As

Publication number Publication date
CY1122352T1 (el) 2021-01-27
LT3278801T (lt) 2020-01-10
US10058536B2 (en) 2018-08-28
SI3278801T1 (sl) 2020-01-31
WO2016159267A1 (ja) 2016-10-06
ES2760673T3 (es) 2020-05-14
DK3278801T3 (da) 2019-12-16
US20180036288A1 (en) 2018-02-08
EP3278801A1 (en) 2018-02-07
EP3278801B1 (en) 2019-11-13
HRP20192213T1 (hr) 2020-03-20
HUE046729T2 (hu) 2020-03-30
JP2018090490A (ja) 2018-06-14
EP3278801A4 (en) 2018-11-14
RS59626B1 (sr) 2020-01-31
PT3278801T (pt) 2019-12-18

Similar Documents

Publication Publication Date Title
IL265260B (en) pharmaceutical preparations
IL265360A (en) Pharmaceutical composition
IL262654A (en) Pharmacy preparation
GB201409471D0 (en) Pharmaceutical composition
IL265349A (en) Pharmaceutical composition
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
GB201409488D0 (en) Pharmaceutical composition
HUE046729T2 (hu) Mirabegront tartalmazó gyógyszerkészítmény
GB201521462D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
GB201506526D0 (en) Medicinal composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
IL255510A (en) Pharmaceutical compositions
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615917D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
IL265436B (en) Pharmacy preparation
SMT202000391T1 (it) Composizione farmaceutica
GB201615910D0 (en) Pharmaceutical composition
SG10201504332VA (en) Pharmaceutical Composition
IL253572A0 (en) A liquid pharmaceutical preparation
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
GB201620519D0 (en) Pharmaceutical composition